29TA Stock Overview Operates as a pharmaceutical royalty company in the United States. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
TherapeuticsMD, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for TherapeuticsMD Historical stock prices Current Share Price US$9.75 52 Week High US$34.75 52 Week Low US$0.11 Beta 1.43 1 Month Change 0% 3 Month Change 1.56% 1 Year Change -67.50% 3 Year Change -94.13% 5 Year Change -95.37% Change since IPO -95.21%
Recent News & Updates
TherapeuticsMD, Inc., Annual General Meeting, Dec 05, 2024 Sep 23
TherapeuticsMD, Inc. Announces Executive Changes Aug 19
TherapeuticsMD, Inc., Annual General Meeting, Jun 26, 2023 May 19 TherapeuticsMd, Inc. Announces Executive Changes
Mayne Pharma (USA), Inc. completed the acquisition of Certain Assets of TherapeuticsMD, Inc. Jan 03
Mayne Pharma Group Limited (ASX:MYX) agreed to acquire Certain Assets of TherapeuticsMD, Inc. (NasdaqGS:TXMD). Dec 06 See more updates
TherapeuticsMD, Inc., Annual General Meeting, Dec 05, 2024 Sep 23
TherapeuticsMD, Inc. Announces Executive Changes Aug 19
TherapeuticsMD, Inc., Annual General Meeting, Jun 26, 2023 May 19 TherapeuticsMd, Inc. Announces Executive Changes
Mayne Pharma (USA), Inc. completed the acquisition of Certain Assets of TherapeuticsMD, Inc. Jan 03
Mayne Pharma Group Limited (ASX:MYX) agreed to acquire Certain Assets of TherapeuticsMD, Inc. (NasdaqGS:TXMD). Dec 06
Mayne Pharma Group Limited (ASX:MYX) agreed to acquire Certain Assets of TherapeuticsMD, Inc. (NasdaqGS:TXMD). Dec 05 Therapeuticsmd, Inc. Appoints Tommy Thompson as Executive Chairman of the Board
TherapeuticsMD, Inc. Appoints Justin Roberts as A Director Aug 30
TherapeuticsMD, Inc. to Report Q2, 2022 Results on Aug 15, 2022 Aug 09
Essex Woodlands Management, Inc. cancelled the acquisition of TherapeuticsMD, Inc. (NasdaqGS:TXMD). Jul 14
TherapeuticsMD, Inc.(NasdaqGS:TXMD) dropped from NASDAQ Biotechnology Index Jun 22
TherapeuticsMD’s Common Stock No Longer Be Listed on Any Public Market Upon Completion of Transaction with EW Healthcare Partners Jun 02
Essex Woodlands Management, Inc. entered into a definitive merger agreement to acquire TherapeuticsMD, Inc. (NasdaqGS:TXMD) for $93 million. Jun 01
Therapeuticsmd, Inc. Receives U.S. Food and Drug Administration (Fda) Approval for Supplemental New Drug Application (Snda) for Annovera® May 21
First quarter 2022 earnings released: US$5.69 loss per share (vs US$5.67 loss in 1Q 2021) May 17
TherapeuticsMD, Inc. to Report Q1, 2022 Results on May 16, 2022 May 12
Forecast breakeven date pushed back to 2024 Apr 27 GoodRx Holdings, Inc. (NasdaqGS:GDRX) completed the acquisition of Vitacare Prescription Services, Inc from from TherapeuticsMD, Inc. (NasdaqGS:TXMD) for approximately $160 million. Apr 15
Forecast breakeven date pushed back to 2024 Mar 13
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Mar 11
TherapeuticsMD, Inc. to Report Q4, 2021 Results on Mar 10, 2022 Mar 03
Robert G. Finizio Notifies TherapeuticsMD, Inc. of His Decision to Resign from the Board of Directors of the Company and as Vice Chair Feb 19
Independent Director recently bought €510k worth of stock Nov 23
Third quarter 2021 earnings released: US$0.11 loss per share (vs US$0.12 loss in 3Q 2020) Nov 12
Forecast to breakeven in 2023 Nov 12
Executive Vice President of Operations Edward Borkowski has left the company Oct 06
TherapeuticsMD Announces Issuance of a J-Code for ANNOVERA® to Be Utilized in the Public Health Sector Aug 25
Independent Director recently bought €619k worth of stock Aug 20
No longer forecast to breakeven Aug 05
Second quarter 2021 earnings released: US$0.11 loss per share (vs US$0.19 loss in 2Q 2020) Aug 05 TherapeuticsMD, Inc.(NasdaqGS:TXMD) dropped from Russell 3000E Value Index
TherapeuticsMD, Inc. Announces Submission of Low Dose BIJUVA® 0.5 mg/100 mg Supplemental New Drug Application to FDA May 26
First quarter 2021 earnings released: US$0.11 loss per share (vs US$0.21 loss in 1Q 2020) May 07
Full year 2020 earnings released: US$0.67 loss per share (vs US$0.71 loss in FY 2019) Mar 03
Revenue beats expectations Mar 03
TherapeuticsMD, Inc. to Report Q4, 2020 Results on Mar 02, 2021 Feb 24
TherapeuticsMD, Inc. has completed a Follow-on Equity Offering in the amount of $110 million. Feb 13
New 90-day high: €1.31 Jan 26
TherapeuticsMD, Inc. Announces the Launch of Just Say Vagina to Encourage Women to Speak Clearly and Directly About Their Reproductive Health Dec 17
New 90-day low: €0.94 Dec 11
New 90-day low: €1.03 Nov 18
Revenue beats expectations Nov 11
Third quarter 2020 earnings released: US$0.12 loss per share Nov 11
TherapeuticsMD, Inc. has completed a Follow-on Equity Offering in the amount of $30 million. Nov 11
New 90-day low: €1.06 Nov 02
TherapeuticsMD, Inc. to Report Q3, 2020 Results on Nov 09, 2020 Oct 30
Knight Therapeutics Inc and TherapeuticsMD, Inc. Announce Health Canada Approval of BIJUVA Sep 22
First half earnings released Aug 07
TherapeuticsMD, Inc. to Report Q2, 2020 Results on Aug 06, 2020 Jul 31
New 90-day high - €1.92 Jul 22 TherapeuticsMD, Inc.(NasdaqGS:TXMD) dropped from S&P Pharmaceuticals Select Industry Index Jun 22
Shareholder Returns 29TA DE Pharmaceuticals DE Market 7D 0% -2.5% -2.6% 1Y -67.5% -15.6% 6.9%
See full shareholder returns
Return vs Market: 29TA underperformed the German Market which returned 5.9% over the past year.
Price Volatility Is 29TA's price volatile compared to industry and market? 29TA volatility 29TA Average Weekly Movement n/a Pharmaceuticals Industry Average Movement 5.4% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.2% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 29TA has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 29TA's volatility change over the past year.
About the Company TherapeuticsMD, Inc. operates as a women’s healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR, which are transdermal patch product candidates; and TX-009HR, an oral progesterone and estradiol formulation.
Show more TherapeuticsMD, Inc. Fundamentals Summary How do TherapeuticsMD's earnings and revenue compare to its market cap? 29TA fundamental statistics Market cap €58.33m Earnings (TTM ) -€27.21m Revenue (TTM ) €92.29m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 29TA income statement (TTM ) Revenue US$91.98m Cost of Revenue US$19.62m Gross Profit US$72.36m Other Expenses US$99.48m Earnings -US$27.12m
Last Reported Earnings
Jun 30, 2022
Earnings per share (EPS) -2.86 Gross Margin 78.67% Net Profit Margin -29.49% Debt/Equity Ratio -348.3%
How did 29TA perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2022/10/04 04:08 End of Day Share Price 2022/07/07 00:00 Earnings 2022/06/30 Annual Earnings 2021/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources TherapeuticsMD, Inc. is covered by 18 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution John Tanner Cantor Fitzgerald & Co. Robert Labick CJS Securities, Inc. Esther Rajavelu Deutsche Bank
Show 15 more analysts 
